IBIO — iBio, Inc. Common Stock
NYSE MKT · Healthcare · Biotechnology
$1.28
+$0.02 (+1.98%)
iBio, Inc. Common Stock (IBIO) is a biotechnology company listed on NYSE MKT. It is led by Martin B. Brenner D.V.M., Ph.D., based in 11750 Sorrento Valley Road, San Diego, CA, United States, 92121, with about 16 employees. iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Latest reported IBIO revenue for 2025-09-30 was $100.0K. Net income was -$5.7M. Revenue was down 75.0% from 2025-06-30 to 2025-09-30. IBIO currently screens at market cap $13.4M.
Use this IBIO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IBIO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IBIO SEC filings page. Lician reads the product cache first so this HTML stays unique to iBio, Inc. Common Stock even when a live quote feed is slow.
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
IBIO Key Statistics
Market Cap
$13.38M
Volume
424,850
Previous Close
$1.42
Day Range
$1.41 – $1.48
EPS
-$1.75
Revenue
$400.00K
Net Income
-$18.38M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+77.8%
Profit Margin
-4594.3%
Employees
16
IBIO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $400.00K | $225.00K | $0.00 | $1.88M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$18.38M | -$24.91M | -$65.01M | -$50.30M |
| EPS (Diluted) | -$1.75 | -$6.50 | -$106.19 | -$5.78 |
Total Assets
$23.18M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$8.58M
Operating Cash Flow
-$15.30M
Free Cash Flow
$0.00
iBio, Inc. Common Stock Company Information
- CEO, Chief Scientific Officer & Director
- Martin B. Brenner D.V.M., Ph.D.
- Headquarters
- 11750 Sorrento Valley Road, San Diego, CA, United States, 92121
- Website
- ibioinc.com
- Phone
- 979 446 0027
- IPO / Founded
- 2008-08-19
- Sector
- Healthcare
- Industry
- Biotechnology